Aurora Cannabis, Inc. (NYSE: ACB) on Tuesday reported a loss for the first quarter of 2022 when its revenues declined 11% from last year.
The Canada-based medical marijuana company reported an EBITDA loss of C$12.1 million for the first quarter, on an adjusted basis, compared to a loss of $58.1 million in the prior-year quarter. Net revenues decreased 11% year-over-year to C$60.1 million during the three-month period.
“Our transformation plan is on track. We continue to strengthen and transform our business while benefitting from broad diversification across our international medical, domestic medical, and adult recreational segments. On a run-rate basis to date, we have executed over $33 million in annualized cost savings, ” said Miguel Martin, chief executive officer of Aurora Cannabis.
Read management/analysts’ comments on Aurora’s Q1 results
Shares of Aurora Cannabis dropped soon after the earnings release on Tuesday evening at the New York Stock Exchange, after closing the regular session higher. The stock has declined 27% since the beginning of 2021.
Most Popular
Should investors worry about Micron’s (MU) weak Q4 results and guidance?
The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,
What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?
Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a
NKE Earnings: Highlights of Nike’s Q1 2023 results
Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss
